everolimus
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pancreatic Neuroendocrine Tumors
Conditions
Pancreatic Neuroendocrine Tumors
Trial Timeline
Mar 14, 2016 → Feb 22, 2024
NCT ID
NCT02842749About everolimus
everolimus is a approved stage product being developed by Novartis for Pancreatic Neuroendocrine Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT02842749. Target conditions include Pancreatic Neuroendocrine Tumors.
What happened to similar drugs?
8 of 20 similar drugs in Pancreatic Neuroendocrine Tumors were approved
Approved (8) Terminated (5) Active (11)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00655252 | Pre-clinical | Completed |
| NCT05108740 | Pre-clinical | Completed |
| NCT05252585 | Approved | Active |
| NCT03525834 | Approved | Completed |
| NCT02962414 | Phase 3 | Active |
| NCT02842749 | Approved | Completed |
| NCT02429869 | Approved | Completed |
| NCT02539459 | Phase 2 | Terminated |
| NCT02687958 | Phase 2 | UNKNOWN |
| NCT02376985 | Phase 3 | Completed |
| NCT02338609 | Approved | Completed |
| NCT02236572 | Phase 2 | Terminated |
| NCT02273752 | Phase 2 | Terminated |
| NCT02201212 | Phase 2 | Completed |
| NCT01864070 | Phase 1 | Withdrawn |
| NCT01997255 | Phase 2 | Withdrawn |
| NCT02096107 | Approved | Completed |
| NCT02017860 | Phase 2 | Completed |
| NCT01636466 | Phase 3 | Terminated |
| NCT01609673 | Pre-clinical | Terminated |
Competing Products
20 competing products in Pancreatic Neuroendocrine Tumors